Evaluation the Effect of Topiramate on the Induction Genotoxicity in Obesity Patients

Abstract

 Topiramate  ( sulfamate - substituted monosaccharide) a weight loss drug used a pharmacotherapeutic  agent for obesity , a study was performed to evaluate the effect of the topiramate  to induce chromosome aberrations (CA) and sister chromatid exchange (SCE) in lymphocytes of obesity patients . CA and SCE, a sensitive measure of chromosome  damage  ,  were  counted  in  peripheral   blood lymphocytes from  32 obesity patients treated with topiramate dose (  6  months with  81mg/day ,  12 months with 129 mg/day) and 16 healthy person as control  group  who  had  never  received topiramate and other drugs during the period of the study. All of the treated patients with topiramate  ,have cells with CA and abnormal SCE frequencies, in analysis ,obesity patients, was significantly increased  CA in 129mg/day and 81mg/day topiramate dose  compared  with  control ( 4.08±1.51 and 3.56±1.21  ) respectively, vs (1.40± 0.81),(P<0.01).Furthermore, a significantly  higher SCE/Cell frequency (10.42 ±0.75and 8.75±0.38) in treated obesity patients with 129 mg/day ,81mg/day dose respectively comparison with their control group (5.91±0.31), (P<0.001). The chromosome damage  and  genotoxics  are related  to the daily dose and may be determined by the duration of treatment .We conclude the patients  treatment with topiramate may be  associated with  genetic toxicity according to byproducts of drug metabolism.